Cambridge Research Biochemicals expands peptide capacity
First firm in Europe to acquire powerful Overture synthesiser, which upgrades the Cleveland firm\'s peptide manufacturing capacity
In the search for new disease-causing target molecules, the peptide libraries produced by Overture can identify the epitopes that cause peoples’ immune systems to react and which may be the key to developing new treatments.
‘The benefit that will be most apparent to our customers will be the ability of Overture's cutting-edge design to speed up the synthesis of peptides and tackle increasingly challenging molecules,’ said Dr Laurent Caron, peptide core technology manager at CRB, based in Cleveland.
The Overture Robotic Peptide Library Synthesiser, developed by Protein Technologies in Tucson, AZ, US allows libraries from 4 to 96 compounds to be made, including overlapping peptides for epitope mapping, alanine-scanning libraries, positional scanning libraries, random libraries, truncation peptide libraries and scrambled peptide libraries for sequence optimisation.
The Overture's flexible software features easy sequence importing, automatic sequence placement, automatic library generation, automated cleaning routines and report and log file generation.
Special features include a safe-response feature, which automatically drains and rinses the resin with solvent when an error occurs, as well as e-mail notification of any problems.
Other features include a workstation utility, which allows syntheses to be created on a PC and then transferred to the Overture with a USB stick. A special door-opening mechanism saves bench space, and an optional solvent cabinet configuration is also available.
Alison White, operations director at CRB, added: ‘This is the second investment in expanding peptide production capacity that we have made in the last six months following our acquisition at the end of 2010 of a Liberty peptide synthesiser, which uses microwave technology to make higher purity peptides up to 10 times faster than by conventional methods.’
You may also like
Trending Articles
You may also like
Ingredients
Cambridge Research Biochemicals releases new DISCOVERY Antibodies catalogue
CRB's new product range will offer the same antibodies that CRB usually offers and includes targets suggested by customers, as well as complex, rare and post translational modification specific custom-made antibodies
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Regulatory
UK clinical trial reforms come into force in largest regulatory overhaul in 20 years
The MHRA and Health Research Authority are implementing the most significant package of clinical trial regulatory reforms in more than two decades, introducing faster assessment routes for lower-risk trials and mandatory registration of trial results
Research & Development
Epitopea receives MHRA approval for first-in-human trial of RNA vaccine for ovarian cancer
The company has received regulatory approval from the MHRA and Regional Ethics Committee to initiate its OVACT Phase I/Ib clinical trial of CryptiVax-1001, an off-the-shelf mRNA immunotherapy targeting high-grade serous ovarian cancer
Manufacturing
Cipla receives FDA approval for first AB-rated generic of Ventolin HFA in $1.5bn US albuterol market
Indian pharmaceutical company Cipla has secured final FDA approval for its Albuterol Sulfate Inhalation Aerosol, becoming the first AB-rated generic therapeutic equivalent of GlaxoSmithKline's Ventolin HFA